


NEWS & COMMENTARIES

abbvie


 capstan
 therapeutics


AbbVie announced it will acquire Capstan Therapeutics, who are behind that work (for a whopping \$2.1B). On the surface, this appears to be a great deal. There's still a long way to go before it reaches patients, but the novelty has resulted in a premium price. <https://www.cnbc.com/2025/06/30/abbvie-to-buy-capstan-therapeutics.html>

The FDA approval of lenacapavir as a twice-yearly injection for the prevention of HIV marks a major milestone for the field and shows how sustained investment in R&D can deliver life-saving breakthroughs. Equitable access to game-changing tools like lenacapavir for PrEP is essential to ending the HIV epidemic. <https://www.who.int/news/item/19-06-2025-fda-approval-of-injectable-lenacapavir-marks-progress-for-hiv-prevention>

SELECTED PUBLICATIONS



How and why funders support engaged research

Bednarek et al., 2025

DOI:10.1073/pnas.2400931121

Global funders are rethinking how research is supported by promoting inclusive, partner-driven approaches. By changing funding practices and investing in supportive infrastructure, they aim to scale research that's more equitable, impactful, and aligned with real-world needs.




Changing climate and socioeconomic factors contribute to global antimicrobial resistance

Li et al., 2025

<https://doi.org/10.1038/s41591-025-03629-3>

A global analysis of 32 million AMR cases shows that climate change is widening resistance gaps between wealthy and low-income countries. Forecasts suggest that sustainable development efforts, like expanding healthcare access, immunization, and sanitation, could reduce AMR by

up to 5.1% by 2050, outperforming antimicrobial use reduction alone. The study underscores the need for integrated, equity-focused strategies to fight AMR in a warming world.



A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial Ma et al., 2025

<https://doi.org/10.1038/s41591-025-03600-2>

YL201, a new antibody–drug conjugate targeting B7H3, demonstrated encouraging results in a global phase 1 trial involving 312 patients with advanced solid tumors. The ADC showed strong responses in small cell lung cancer (63.9% ORR), nasopharyngeal carcinoma (48.6%), and other tumor types, with manageable side effects.



Biologic Drugs and Medicare Price Negotiation

Hwang et al., 2025

DOI: [10.1056/NEJMp2413686](https://doi.org/10.1056/NEJMp2413686)

Biologic drugs, which make up a growing share of Medicare spending, receive more lenient treatment under the Medicare Drug Price Negotiation Program than small-molecule drugs. Current rules delay negotiations for biologics by four years and exclude some from early selection. Experts suggest that reforming these terms,

especially for biologics under Medicare Part B, could better control rising drug costs.



Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine

Stewart et al., 2025

DOI :[10.1073/pnas.2503570122](https://doi.org/10.1073/pnas.2503570122)

Suzetrigine, a newly approved Nav1.8 sodium channel inhibitor for acute pain, reduces (but does not fully block) electrical activity in pain-sensing neurons. This is partly due to continued signaling through other sodium channels like Nav1.7. The findings suggest that targeting Nav1.8

alone may offer only partial relief, highlighting the need for broader strategies in pain management.



The microbiota vault initiative: safeguarding Earth's microbial heritage for future generations

Dominguez-Bello et al., 2025

<https://doi.org/10.1038/s41467-025-61008-5>

Microbial ecosystems are crucial for health but are threatened by human activities. Their decline affects environmental stability and biodiversity. The Microbiota Vault Initiative aims to protect microbial diversity by archiving it and promoting ethical collaboration among

researchers. It supports microbiome resilience amid environmental changes.



Fine structural design of 3β HSD1 inhibitors for prostate cancer therapy

He et al., 2025

DOI:10.1073/pnas.2422267122

Advanced computational methods have led to the development of a 3β HSD1 inhibitor, HEAL-116, which has shown improved binding properties, oral absorption, and potent antitumor effects in preclinical models. This work demonstrates the feasibility of using predicted structural models for optimizing lead compounds for prostate cancer

therapy.




Generative AI without guardrails can harm learning: Evidence from high school mathematics

Bastan et al., 2025

DOI :10.1073/pnas.2422633122

A large high school study found that while GPT-4–based tutoring improves short-term math performance, students relying on it may learn less when AI help is removed. However, using teacher-designed hints instead of direct answers helps preserve skill development. The study

underscores the need for careful AI integration to support and not replace student learning.




Retinoic acid receptor assembly dynamics governs dual functions in cochlear organogenesis

Chakraborty et al., 2025

DOI :10.1073/pnas.2426739122

Sensory hair cells in mammals do not regenerate, leading to hearing loss. Retinoic acid, a signaling molecule, induces hair cell differentiation in embryonic cochlea. Understanding its molecular mechanisms could help develop therapeutic strategies for hearing loss. This study

show that retinoic acid signals through a receptor complex that either activates or represses prosensory gene expression depending on retinoic acid levels.



target space and establishing a platform for drug target elimination.

Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition

Petzold et al., 2025

DOI: [10.1126/science.adt6736](https://doi.org/10.1126/science.adt6736)

The CRL4CRBN E3 ubiquitin ligase targets molecular glue degrader compounds, causing the degradation of clinically relevant neosubstrate proteins. Computational mining predicts over 1600 CRBN-compatible G-loop proteins and identifies VAV1's binding mode, broadening the CRBN




BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature-positive castration-resistant prostate cancer

Shukla et al., 2025

<https://doi.org/10.1172/JCI180378>

A subgroup of castration-resistant prostate cancer (CRPC) expresses a gastrointestinal transcriptome, which correlates with adverse clinical outcomes and shorter overall survival. Bromo- and extra-terminal domain inhibitors (BETi)

downregulated HNF1A, HNF4G, and the GI transcriptome in CRPC models, selectively inhibiting growth and gene expression. Restoration of HNF4G expression rescued target gene expression without rescuing BRD4 binding.



High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages

Armesilla-Diaz et al., 2025

<https://doi.org/10.1128/aac.01613-24>

The study scales up hiPSC-Macs production for high-throughput drug screening against Mycobacterium tuberculosis (Mtb). A library of 200,000 compounds was interrogated in Mtb-infected hiPSC-Macs, with a Z-score above 0.3. The assay showed sensitivity to identify

compounds targeting host-pathogen interactions during Mtb infection, with 223 qualified hits selected for further progression.

RECOMMENDED EVENTS & JOB CORNER



High-content Imaging and Flow Cytometry 2025

The 9th biennial High Content Imaging and Flow Cytometry in Drug Discovery 2025 will be held at GSK Medicines Research Centre, Stevenage.

Date: 19 – 20 November 2025

<https://elrig.org/portfolio/high-content-imaging-and-flow-cytometry-2025/>



Disease Modeling and Therapeutics (DMT) Conference 2025

The Disease Modeling and Therapeutics (DMT) Conference is now accepting abstract submissions. We invite researchers, scientists, students, and clinicians to submit their latest findings on disease modeling, stem cell research, organoid technologies, animal models, and the development of novel therapeutic strategies.

<https://lnkd.in/dkhuM6cD>



Call for 20 Assistant Professor positions

Karolinska Institutet is a world-leading medical university with a long and proud history of ground-breaking research. We are now recruiting outstanding early-career researchers with particularly excellent scientific merits and future potential. We are looking for inspiring, curious and creative candidates to start their career as Assistant Professor with us in several subject areas.

<https://ki.se/en/about-ki/jobs-at-ki/join-a-global-community-of-excellence>



150 Postdoctoral Research Fellowship Awards at UM.

We are seeking exceptional postdoctoral candidates with a proven track record of research excellence, originality, and the drive to make an international impact. Position yourself at the forefront of impactful research. Apply now!

<https://umresearch.um.edu.my/join-us/post-doctoral-fellowship/>



We are **HIRING**

WHO

HOME-BASED RESEARCH CONSULTANCY
ROLE AT WHO
\$8000-\$12500 MONTHLY

Apply Now

World Health Organization Hiring a Home-Based Research Consultant

Are you a global health research expert looking for a fully remote, high-impact consultancy? The World Health Organization (WHO) is seeking a Research Consultant to contribute cutting-edge analysis, evidence synthesis, and policy recommendations in support of its global health mandates. This home-based opportunity offers both flexibility and the chance to work with one of the world's most respected international health bodies.

<https://careers.who.int/careersection/ex/jobdetail.ftl?job=2502113&tz=GMT%2B02%3A00&tzname=Africa%2FHarare>

The Novartis Innovation Postdoctoral Fellowship



Innovation Postdoctoral Fellow Neuronal Aging

Innovation Fellowship track of the Novartis Postdoctoral Fellowship Program.

This applied research program is designed to change the way we approach drug discovery.

<https://www.novartis.com/careers/career-search/job/details/req-10057139-innovation-postdoctoral-fellow-neuronal-aging>



Commercial Sales Representative

Babraham, England, United Kingdom

We are seeking a highly motivated Commercial Sales Representative to join our growing team at Axol Bioscience, a leader in the scientific industry. This role will be critical in supporting our sales strategies by managing inbound leads, prospecting new business opportunities and maintaining strong relationships with clients in the scientific community, including laboratories, research institutions and industrial partners.

<https://axolbio.com/careers-at-axol-bioscience/>

If you want your article of be featured with us email us @ admin@algeriansca-dz.org

